Fish oil supplements in patients with chronic kidney disease
Abstract
Cardiovascular disease (CVD) accounts for most of the increased morbidity and mortality associated with in chronic kidney disease (CKD). Cardiovascular risk emerges early in CKD, initially driven by atherosclerotic events but later dominated by heart failure and sudden cardiac death. This transition reflects progressive arteriosclerosis and the development of CKD-associated cardiomyopathy. Although patients receiving dialysis experience the highest cardiovascular risk, established atherosclerotic therapies such as lipid-lowering agents offer limited benefit at this stage. Recent therapeutic advances, including SGLT2 inhibitors, GLP1 receptor agonists and mineralocorticoid receptor antagonists, have improved outcomes in non-dialysis CKD, but the high cardiovascular mortality of dialysis patients remains largely unchanged, with multiple interventions having failed to demonstrate benefit. In this review, we outline the pleiotropic actions of omega-3 polyunsaturated fatty acids (PUFA) including anti-inflammatory, anti-oxidative, anti-thrombotic, plaque stabilising and membrane modulating effects. We discuss the PISCES trial that reported large reductions in cardiovascular events with high dose fish oil supplementation (1.6 g EPA + 0.8 g DHA daily) in 1228 haemodialysis patients followed up for 3.5 years. This treatment lowered events comprising the primary endpoint by 43% with similar reductions observed in cardiac death, myocardial infarction and stroke. Prior studies of fish…
Read the paper
Related studies
- eggNOG 5.0: a hierarchical, functionally and phylogenetically annotated orthology resource based on 5090 organisms and 2502 viruses
- Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
- OptiType: precision HLA typing from next-generation sequencing data
- Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications
- Saccharomyces cerevisiae cells have three Omega class glutathione S-transferases acting as 1-Cys thiol transferases
- Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.